Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group, dose‐comparison study
- 3 October 2012
- journal article
- research article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 27 (3) , e376-e383
Abstract
Background Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works intracellularly to modulate pro‐inflammatory and anti‐inflammatory mediator production.Objective Assess apremilast efficacy and safety in moderate to severe plaque psoriasis.Methods Phase II, 12‐week, multicenter, double‐blind, placebo‐controlled, parallel‐group, dose‐comparison study of 259 subjects randomized 1 : 1 : 1 to placebo, apremilast 20 mg QD or apremilast 20 mg BID.Results More subjects receiving apremilast 20 mg BID achieved ≥ 75% reduction in Psoriasis Area and Severity Index (PASI‐75) vs. placebo (24.4% vs. 10.3%; P = 0.023). A similar proportion of subjects receiving apremilast 20 mg QD and placebo achieved PASI‐75 at week 12 [9/87 (10.3%, each group)]. Mean per cent reduction in PASI from baseline was 17.4% for placebo, 30.3% for apremilast 20 mg QD (P = 0.021 vs. placebo) and 52.1% for apremilast 20 mg BID (P < 0.001). Apremilast 20 mg BID significantly decreased mean body surface area involvement vs. placebo (30.8% vs. 3.2%; P < 0.001). The most common adverse events were headache, nasopharyngitis, diarrhoea and nausea. Most events (> 90%) were mild to moderate and did not lead to study discontinuation. Serious adverse events occurred in four placebo subjects (panic attack, hospitalization for rehabilitation, hospitalization for alcoholism, worsening psoriasis), one receiving apremilast 20 mg QD (knee surgery) and in one receiving apremilast 20 mg BID (worsening psoriasis). The panic attack was considered treatment‐related; both cases of worsening psoriasis occurred after medication discontinuation. No deaths or opportunistic infections were reported.Conclusion Apremilast 20 mg BID for 12 weeks was effective and well tolerated in subjects with moderate to severe plaque psoriasis.Keywords
This publication has 22 references indexed in Scilit:
- High Prevalence of Potential Drug-Drug Interactions for Psoriasis Patients Prescribed Methotrexate or Cyclosporine for Psoriasis: Associated Clinical and Economic Outcomes in Real-World PracticeDermatology, 2010
- Co-morbidity and Age-related Prevalence of Psoriasis: Analysis of Health Insurance Data in GermanyActa Dermato-Venereologica, 2010
- European S3‐Guidelines on the systemic treatment of psoriasis vulgarisJournal of the European Academy of Dermatology and Venereology, 2009
- The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: Results from NHANES 2003-2004Journal of the American Academy of Dermatology, 2009
- A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritisAnnals of the Rheumatic Diseases, 2008
- Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open‐label, multicenter, Phase IIIb studyInternational Journal of Dermatology, 2007
- German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version)Archives of Dermatological Research, 2007
- Adherence to treatment in patients with psoriasisJournal of the European Academy of Dermatology and Venereology, 2006
- Systemic therapies for psoriasis: understanding current and newly emerging therapiesSeminars in Cutaneous Medicine and Surgery, 2003
- PsoriasisThe Lancet, 2003